tetano
Editor, Senior Moderator
Int J Hematol
. 2023 May 23.
doi: 10.1007/s12185-023-03618-7. Online ahead of print. New onset of hypomegakaryocytic thrombocytopenia with the potential for progression to aplastic anemia after BNT162b2 mRNA COVID-19 vaccination
Mirei Kobayashi[SUP] 1 [/SUP], Akio Mori[SUP] 2 [/SUP], Yoshitaka Oda[SUP] 3 [/SUP], Emi Yokoyama[SUP] 2 [/SUP], Minoru Kanaya[SUP] 2 [/SUP], Koh Izumiyama[SUP] 2 [/SUP], Makoto Saito[SUP] 2 [/SUP], Shinya Tanaka[SUP] 3 4 [/SUP], Masanobu Morioka[SUP] 2 [/SUP], Takeshi Kondo[SUP] 2 [/SUP]
Affiliations
Vaccination with a coronavirus disease-2019 (COVID-19) vaccine is an effective public health measure for reducing the risk of infection and severe complications from COVID-19. However, serious hematological complications after COVID-19 vaccination have been reported. Here, we report a case of new-onset hypomegakaryocytic thrombocytopenia (HMT) with the potential for progression to aplastic anemia (AA) that developed in a 46-year-old man 4 days after the fourth mRNA COVID-19 vaccination. Platelet count rapidly decreased after vaccination and white blood cell count declined subsequently. Bone marrow examination immediately after disease onset showed severely hypocellular marrow (cellularity of almost 0%) in the absence of fibrosis, findings that were consistent with AA. Since the severity of pancytopenia did not meet the diagnostic criteria for AA, the patient was diagnosed with HMT that could progress to AA. Treatment with eltrombopag and cyclosporine was started immediately after diagnosis and cytopenia improved. Although it is difficult to determine whether the post-vaccination cytopenia was vaccine induced or accidental because the association was chronological, vaccination with an mRNA-based COVID-19 vaccine may be associated with development of HMT/AA. Therefore, physicians should be aware of this rare, but serious adverse event and promptly provide appropriate treatment.
Keywords: Aplastic anemia (AA); COVID-19; Hypomegakaryocytic thrombocytopenia (HMT); SARS-CoV-2; Vaccine.
. 2023 May 23.
doi: 10.1007/s12185-023-03618-7. Online ahead of print. New onset of hypomegakaryocytic thrombocytopenia with the potential for progression to aplastic anemia after BNT162b2 mRNA COVID-19 vaccination
Mirei Kobayashi[SUP] 1 [/SUP], Akio Mori[SUP] 2 [/SUP], Yoshitaka Oda[SUP] 3 [/SUP], Emi Yokoyama[SUP] 2 [/SUP], Minoru Kanaya[SUP] 2 [/SUP], Koh Izumiyama[SUP] 2 [/SUP], Makoto Saito[SUP] 2 [/SUP], Shinya Tanaka[SUP] 3 4 [/SUP], Masanobu Morioka[SUP] 2 [/SUP], Takeshi Kondo[SUP] 2 [/SUP]
Affiliations
- PMID: 37219678
- DOI: 10.1007/s12185-023-03618-7
Vaccination with a coronavirus disease-2019 (COVID-19) vaccine is an effective public health measure for reducing the risk of infection and severe complications from COVID-19. However, serious hematological complications after COVID-19 vaccination have been reported. Here, we report a case of new-onset hypomegakaryocytic thrombocytopenia (HMT) with the potential for progression to aplastic anemia (AA) that developed in a 46-year-old man 4 days after the fourth mRNA COVID-19 vaccination. Platelet count rapidly decreased after vaccination and white blood cell count declined subsequently. Bone marrow examination immediately after disease onset showed severely hypocellular marrow (cellularity of almost 0%) in the absence of fibrosis, findings that were consistent with AA. Since the severity of pancytopenia did not meet the diagnostic criteria for AA, the patient was diagnosed with HMT that could progress to AA. Treatment with eltrombopag and cyclosporine was started immediately after diagnosis and cytopenia improved. Although it is difficult to determine whether the post-vaccination cytopenia was vaccine induced or accidental because the association was chronological, vaccination with an mRNA-based COVID-19 vaccine may be associated with development of HMT/AA. Therefore, physicians should be aware of this rare, but serious adverse event and promptly provide appropriate treatment.
Keywords: Aplastic anemia (AA); COVID-19; Hypomegakaryocytic thrombocytopenia (HMT); SARS-CoV-2; Vaccine.